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Abstract
Major depressive disorder affects an estimate of 5% of the population with nearly 1 ‑third of patients failing to achieve 
remission with conventional pharmacological treatment. Esketamine, a novel rapid ‑acting antidepressant, with a 
noncompetitive antagonism on N ‑methyl ‑D ‑Aspartate receptor, have been recently approved by Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) for treatment ‑resistant depression. 
Here, we report a clinical case of a 42 ‑year ‑old Caucasian woman who endured many years with severe depressive 
symptoms and high functional impairment. Previous treatments included cognitive behavioral therapy, numerous 
pharmacological trials with antidepressants and augmentation agents, and neurostimulation approaches. Upon treatment 
with esketamine, the patient presented remarkable clinical recovery. Psychometric assessments determined an acute 
reduction on the MADRS score after 1 week and progressive recovery of the depressive symptoms on the following 
weeks. Likewise, PHQ ‑9 scale assessments, evaluating the relative frequency of depressive symptoms. and the Sheehan 
scale, assessing functional recovery, also determined a pronounced symptomatic relief.
Keywords:  Antidepressive Agents; Depressive Disorder, Major/drug therapy; Depressive Disorder, Treatment‑
‑Resistant/drug therapy; Esketamine/administration & dosage
Resumo
A perturbação depressiva major afeta cerca de 5% da população e quase 1 ‑terço dos doentes não consegue atingir 
remissão com o tratamento farmacológico convencional. Escetamina, um novo antidepressivo de ação rápida, com 
antagonismo não competitivo do receptor N ‑metil ‑D ‑aspartato, foi recentemente aprovado pela Food and Drug 
Administration (FDA) e European Medicines Agency (EMA) para o tratamento de depressão resistente ao tratamento. 
Aqui, relatamos o caso clínico de uma mulher caucasiana de 42 anos que padeceu durante muitos anos de sintomas 
depressivos graves e de grande compromisso funcional. Os tratamentos anteriores incluíram terapia cognitivo‑
‑comportamental, vários ciclos de tratamento farmacológico com antidepressivos e agentes de aumento e técnicas de 
neuroestimulação. Após tratamento com escetamina, a doente apresentou uma notável recuperação clínica. Avaliações 
psicométricas determinaram uma redução considerável na pontuação MADRS após uma semana e recuperação 
progressiva dos sintomas depressivos nas semanas seguintes. Da mesma forma, as avaliações com a escala de PHQ‑
‑9, que avalia a frequência relativa de sintomas depressivos, e a escala de Sheehan, que avalia a recuperação funcional, 
também determinaram alívio sintomático muito pronunciado.
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INTRODUCTION 
Major depressive disorder is a highly debilitating disease 
associated with a massive socioeconomic burden.1,2 Al‑
though treatment with regular antidepressants and psycho‑
therapy is effective, one ‑third of patients fail to achieve 
remission.3,4 Patients who have not responded to at least 
2 different antidepressant treatment approaches in the 
current depressive episode are diagnosed with treatment‑
‑resistant depression (TRD).5 Even considering the patients 
who attain partial response with initial antidepressant 
trials, many endure several weeks with severe depressive 
symptoms which increases the risk of suicidal behaviour.6 
For these patients with TRD and prolonged response to 
conventional treatments, the most common clinical rec‑
ommendation includes neurostimulation approaches. 
Although, electroconvulsive therapy (ECT) can improve 
depressive symptoms, a considerable percentage remain 
symptomatic or develop cognitive side effects.7 Another 
therapeutic possibility is repetitive transcranial magnetic 
stimulation (rTMS). However, the requirement of highly 
sophisticated equipment and technical skills have greatly 
limited the treatment of large numbers of patients.
Esketamine, a novel rapid ‑acting antidepressant with a 
noncompetitive antagonism of the N ‑methyl ‑D ‑Aspartate 
receptor, have been recently approved by Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA) for TRD.8 Here, we report a case study of a patient 
with TRD that was successfully treated with esketamine. 
This clinical case provides further evidence of clinically 
meaningful efficacy of this approach particularly when 
combined with conventional antidepressants.
CASE REPORT
A 42 ‑year ‑old Caucasian woman, married, with two 
children and working as a full ‑time professor in a public 
university developed depressed mood, apathy, anhedonia, 
fatigue, psychic anxiety, and loss of self ‑esteem in the Au‑
tumn of 2013. Antidepressive treatment was initiated with 
doses being progressively adjusted to 60 mg of fluoxetine 
and 10 mg of diazepam (tid). Clinical recovery was very 
limited, and the patient was unable to continue her job. 
A second trial of antidepressants was tried using clomip‑
ramine (75 mg, tid) and quetiapine (200 mg) but the pa‑
tient maintained a progressive clinical decline with further 
complains of adynamia, clinophilia, psychomotor retar‑
dation, and impaired memory and concentration. Medical 
treatment was then further augmented using venlafaxine 
(300 mg), bupropion (300 mg), mirtazapine (30 mg) and 
quetiapine (200 mg). The patient was also referred to cog‑
nitive behavioral therapy which she followed for 2 years. 
Nevertheless, this third attempt was also unable to pro‑
mote symptomatic relief and the disease further evolved 
to suicidal ideation. Specifically, the patient was found 
to be carrying a kitchen knife in her handbag and driving 
around a cliff region. Both plans were hold with resolute 
suicidal intent demanding treatment in an inpatient setting. 
Despite remission of the suicidal ideation, the patient was 
still unable to work and was finally proposed to retire at 
46 ‑years ‑old.  
rTMS was also attempted with 20 sessions stimulating 
the left dorsolateral pre ‑frontal cortex.9 Clinical recovery 
was not observed and therefore the patient maintained 
depressed mood, adynamia, physic anxiety and sense of 
hopelessness that severely conditioned her competence to 
fulfil household duties and taking care of her children.
Recently, upon the approval of esketamine by the Por‑
tuguese Authority for Medication (Infarmed), a new 
therapeutic approach could be considered for patients 
with TRD. Esketamine was supplied before marketing 
authorization through an early access program.10 Taking 
advantage of the early access program, patient was en‑
rolled in the first esketamine TRD protocol implemented 
in Portugal. Briefly, patient comfortably resting in a hos‑
pital room, with low sound and visual stimulation, self‑
‑administrated esketamine according to the manufacturer 
instructions.  Specifically, the current clinical case was 
treated twice weekly with 56 mg of esketamine during 
weeks 1 to 3 and twice weekly with 84 mg of esketamine 
during week 4 (induction phase). Maintenance phase 
included once weekly with 84 mg of esketamine during 
weeks 9 to 14 (Fig. 1). 
Figure 1. Schematic representation of the induction and maintenance phases of esketamine treatment.
Psychometric assessments during the first week determined 
a remarkable clinical recovery with considerable reduction 
of the MADRS11 score. During week 2 and 3, the clinical 
recovery was also found to be modest (Fig. 2) and there‑
fore it was decided to titrate the esketamine dose to 84 mg. 
Patient continue to recover with a gradual and progressive 
reductions of MADRS score on the following weeks (Fig. 
2). PDH ‑912 assessment, focusing on the relative frequency 
of depressive symptoms, and SDS13 assessments, evaluat‑
ing functional recovery, also determined progressive score 
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reduction up weeks 4 and 5, respectively. In addition, main‑
tenance phase (weeks 5 to 14), consisting of weekly treat‑
ments with 84 mg of esketamine, successfully preserved the 
patient at an asymptomatic state (Fig. 2).
Figure 2. Psychometric assessment during induction phase 
(weeks 1 to 4) and maintenance Phase (weeks 5 to 14) of 
esketamine treatment. 
Clinical assessment using MADRS, PHQ ‑9 and SDS were 
conducted once weekly. Induction phase consisting of 56 
mg of esketamine twice weekly during weeks 1 to 3 and 84 
mg of esketamine twice weekly during week 4 resulted in 
remarkable reduction of the MADRS score during the first 
week and progressive recovery on the following weeks. 
PHQ ‑9, evaluating the relative frequency of depressive 
symptoms, and SDS, evaluating the functional recovery, 
also determined progressive score reduction. Maintenance 
phase consisting of weekly treatment using 84 mg of 
esketamine weekly (weeks 5 to 14) resulted in successful‑
ly preservation of the patient asymptomatic state.
Regarding side effects, the patient experienced mild 
somnolence and dizziness, prolix speech, and auditory 
hyperesthesia. These side effects lasted only for about 50 
minutes and were clearly more pronounced in the first few 
treatment sessions. 
DISCUSSION
The newly available esketamine is expected to address an 
unmet medical need for the patients enduring TRD and 
for patients requiring rapid antidepressant action. Indeed, 
previous studies have demonstrated prompt onset and per‑
sistent efficacy compared with placebo in TRD and suicidal 
patients.14,15 Higher antidepressant efficacy and long ‑term 
maintenance was also demonstrated for esketamine plus 
oral antidepressant group in comparison to placebo plus 
oral antidepressant with meaningful reduction of MADRS 
score at earlier time points and a significantly greater re‑
duction being observed at day 28.16,17 Besides the medical 
evaluation, the clinical benefits are also greatly appreci‑
ated by the patients enrolling the esketamine plus antide‑
pressant group.8 Also supporting this data, the clinical case 
presented here has shown a pronounced clinical recovery 
and sustained reductions in MADRS, Sheehan and PHQ‑
‑9 scores. Importantly, the acute clinical improvement 
during the first week of treatment further emphasizes the 
hypothesis that esketamine might be beneficial for suicidal 
patients and even evocative of a novel concept of treat‑
ment whereas the maintenance of the remarkable relief 
confirms the role of esketamine for TRD patients (Fig. 2). 
Of note, the described patient continues to be treated with 
the oral antidepressants and esketamine, up to this date, 
maintaining a euthymic mood status and being grateful of 
their functional improvement. Taken together the current 
manuscript reinforces the safety, feasibility, and clinical 
relevance of esketamine as an adjunctive approach to the 
conventional treatment of TRD patients and as a potential 
alternative to neurostimulation techniques. 
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